antibodies
Abcam to License Phage Library from Twist Bioscience for Antibody Discovery, Diagnostics
The deal "lays the foundations for a long-term collaboration with Abcam to drive new commercial opportunities," Twist CEO Emily Leproust said.
Twist Bioscience, Artisan Development Labs Collaborate on Antibody Discovery, Cell Therapies
Twist will receive upfront technology access and project fees; success-based clinical, regulatory, and commercial milestones; and royalties.
With $40 million in VC funding, the firm also intends to hire an international sales force and build a new generation of Cyto-Mine instruments with laser optics.
The expansion is one of several updates on the DNA synthesis firm's plans for its fiscal year 2022, which began last month.
Twist Bioscience Reports 17 Percent Growth of Fiscal Q4 Revenues, to Acquire Abveris
The firm has entered into a definitive agreement to acquire Abveris, an antibody discovery company, for up to $190 million in stock and cash.